SAR 438544

Drug Profile

SAR 438544

Alternative Names: SAR438544

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 01 Aug 2016 Discontinued - Phase-I for Type-1 diabetes mellitus in USA (SC)
  • 24 Dec 2015 Sanofi plans a phase I trial for Type-1 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT02635243)
  • 17 Dec 2015 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC) (NCT02625636)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top